Overview Request Sample Pages Request Customization Download PDF
You are viewing: South Korea Veterinary Biologics Market analysis
Part of: Veterinary Biologics Market (Global)

The South Korea Veterinary Biologics Market was valued at $16.27 Million in 2025 and projected to reach to $20.68 Million by 2030, representing a compound annual growth rate of 4.9%. South Korea's veterinary biologics market is poised for steady expansion driven by increasing pet ownership, growing consumer spending on animal healthcare, and rising awareness of preventive medicine.

South Korea Veterinary Biologics Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Veterinary Biologics Market Trends and Insights

  • South Korea's advanced veterinary healthcare infrastructure and rising pet ownership drive demand for innovative biologic therapeutics and vaccines.
  • The market in South Korea reflects strong adoption of preventive care solutions and increasing investment in animal health research and development. Growth in South Korea's veterinary biologics sector is supported by regulatory frameworks that encourage product innovation and the country's emphasis on food safety and livestock health management.
  • South Korea's position as a technology-forward nation facilitates the integration of cutting-edge biologic solutions in veterinary practice.
  • Between 2025 and 2030, South Korea is expected to see sustained expansion driven by companion animal healthcare spending and biosecurity initiatives in commercial farming..

Key Market Statistics

  • CAGR (2025-2030) 4.9% CAGR
  • Market Size, 2025 ~USD 16.27 Million
  • Forecast, 2030 ~USD 20.68 Million
  • Country South Korea

South Korea Veterinary Biologics Market Overview

Market Valuation :

South Korea's veterinary biologics market is valued at USD 16.27 million in 2025, with projections to reach USD 20.68 million by 2030, representing steady growth in the region's animal healthcare sector.

Growth Trajectory :

The market expands at a CAGR of 4.9% through 2030, slightly below the global average of 5.2%, reflecting South Korea's mature yet developing veterinary biologics landscape.

Pet Ownership Surge :

Rising pet ownership in South Korea, particularly among urban millennials and affluent households, drives increased demand for premium biologic therapeutics, vaccines, and preventive care solutions.

Advanced Healthcare Infrastructure :

South Korea's sophisticated veterinary healthcare system and high adoption of innovative biologic treatments position the country as a key market for premium animal health products and services.

South Korea Veterinary Biologics Market Dynamics

  • The country's advanced veterinary infrastructure and strong regulatory framework support the adoption of innovative biologic therapeutics and vaccines.
  • Pet owners in South Korea demonstrate high willingness to invest in premium healthcare solutions, creating opportunities for differentiated biologic products. The market will benefit from technological advancements in vaccine development, immunotherapy, and personalized veterinary medicine.
  • Collaborations between South Korean veterinary institutions and international biotech firms are expected to accelerate product innovation.
  • However, market growth may be tempered by regulatory complexities and competition from established players, requiring strategic positioning and localized marketing approaches..

Related Ecosystem

Animal Health

Top Technologies
  • Polymerase Chain Reaction (PCR) Tests
  • Porcine
  • Immunodiagnostics
  • Lateral Flow Assays
  • Microarrays
Top Companies
  • Zoetis Inc.
  • Patterson Companies, Inc.
  • Virbac
  • Elanco Animal Health Incorporated
  • BOEHRINGER INGELHEIM GMBH

    Key Takeaways

    • South Korea's veterinary biologics market is valued at USD 16.27 million in 2025 with a projected value of USD 20.68 million by 2030.
    • South Korea demonstrates a 4.9% CAGR, reflecting steady growth in biologic vaccine and therapeutic adoption across companion and livestock sectors.
    • South Korea's advanced regulatory environment and technology infrastructure support rapid commercialization of innovative veterinary biologic products.
    • South Korea's rising pet ownership and emphasis on food safety drive sustained demand for preventive biologic solutions through 2030.

    Veterinary Biologics Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CANINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 5.2% from 2025 to 2030
    Largest Segment INJECTABLE ROUTE OF ADMINISTRATION (Route Of Administration)
    Market Size Base Year (Billions) ~USD 2.72 (2025)
    Revenue Forecast (Billions) ~USD 3.51 (2030)
    Segments Covered Product Type, Animal Type, Type, Route Of Administration, Application, End User

    South Korea Veterinary Biologics Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Product Type

    • Diagnostic Kits
    • Immunodmodulators & Immunostimulants
    • Immunoglobulins & Antitoxins
    • Immunomodulators & Immunostimulants
    • Immuoglobulins & Antitoxins
    • Monoclonal Anitbodies
    • Monoclonal Antibodies

    By Animal Type

    • Companion Animal
    • Companion Animals
    • Livestock Animal
    • Livestock Animals

    By Type

    • Bovine
    • Canine
    • Equine
    • Feline
    • Intramuscular Route Of Administration
    • Intravenous Route Of Administration
    • Other Injectable Route Of Administration
    • Porcine
    • Poultry
    • Small Ruminant
    • Subcutaneous Route Of Administration

    By Route Of Administration

    • Injectable Route Of Administration
    • Oral Route Of Administration
    • Other Routes Of Administration

    By Application

    • Dermatology
    • Diagnostic Testing
    • Diagnostic Tetsing
    • Infectious Disease Prevention
    • Oncology
    • Other Applications
    • Pain Management

    By End User

    • Other End Users
    • Veterinary Diagnostic Labs
    • Veterinary Hospitals & Clinics

    Target Audience

    • Veterinary Pharmaceutical Companies : Manufacturers and distributors of biologic therapeutics and vaccines need South Korea-specific market data to develop localized product portfolios and identify partnership opportunities with local veterinary providers.
    • Investment & Private Equity Firms : Investors evaluating opportunities in South Korea's animal health sector require detailed market sizing, growth forecasts, and competitive analysis to assess ROI and portfolio fit.
    • Veterinary Healthcare Providers : Veterinary clinics and animal hospitals in South Korea need market intelligence on emerging biologic products, treatment trends, and consumer demand to optimize service offerings and procurement strategies.
    • Biotech & Research Institutions : Academic and research organizations focused on veterinary medicine require South Korea market data to identify collaboration opportunities, funding prospects, and commercialization pathways for innovations.
    • Market Entry & Expansion Strategists : Companies planning to enter or expand in South Korea's veterinary biologics market need region-specific insights on regulatory requirements, competitive positioning, and consumer preferences to minimize risk.

    Key Companies in the South Korea Veterinary Biologics Market

    CompanyHQOwnershipStrongest segments
    IDEXXUnited StatesPublic CompanyCompanion Animal Group (in-clinic diagnostics, reference labs, services, software),Water Quality Products,Livestock, Poultry and Dairy (including related diagnostics),
    ELANCOUnited StatesPublic CompanyCompanion animal parasiticides (Seresto, K-9 Advantage, Advantix, Advocate, Credelio Family, Interceptor Plus, Drontal),Companion animal vaccines and therapeutics (Galliprant, Atopica, Milbemax, Onsior, Tru Family),Farm animal feed additives and productivity enhancers (Rumensin, Experior, Hemicell, Surmax, Pulmotil),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations),Vaccines (Gardasil, pediatric and adult vaccines including Vaxneuvance, Capvaxive),Cardiovascular, pulmonary hypertension and specialty (Winrevair, Adempas/Verquvo, Ohtuvayre, others),
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    NEOGEN CORPORATIONUnited StatesPublic CompanyFood Safety diagnostics, media, and sanitation,Animal Safety instruments, care products, and biosecurity,Genomics services for livestock and companion animals,
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Systems,Life Science Reagents and Consumables,
    IMMUCELL CORPORATIONUnited StatesPublic CompanyFirst Defense (core scours prevention),Tri-Shield First Defense,Dual-Force First Defense and related formulations,

    IDEXX

    IDEXX is a public company founded in 1983 and headquartered in the United States, employing 11,000 people.

    ELANCO

    Elanco is a public company founded in 1954 in the United States with 9,650 employees.

    MERCK & CO., INC.

    Merck & Co., Inc. is a public pharmaceutical company founded in 1891 and based in the United States, with 74,000 employees.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a public company founded in 1956 in the United States and employs 125,000 people.

    NEOGEN CORPORATION

    Neogen Corporation is a public company founded in 1981 in the United States with 2,974 employees.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States and employs 7,450 people.

    IMMUCELL CORPORATION

    ImmuCell Corporation is a public company founded in 1982 in the United States with 73 employees.

    Reasons to Buy this Report

    • Market-Specific Sizing & Forecasts : Access precise valuation data for South Korea's veterinary biologics market (USD 16.27M in 2025, USD 20.68M in 2030) with country-specific CAGR of 4.9% to inform investment and expansion decisions.
    • Competitive Landscape Intelligence : Understand South Korea's unique competitive dynamics, regulatory environment, and market entry barriers specific to the region's advanced veterinary healthcare infrastructure.
    • Pet Ownership & Consumer Insights : Leverage detailed analysis of South Korea's rising pet ownership trends, consumer spending patterns, and preferences for premium biologic therapeutics to tailor product strategies.
    • Growth Opportunity Identification : Identify high-potential segments within South Korea's market, including vaccine development, immunotherapy, and preventive care solutions aligned with local demand drivers.
    • Strategic Planning & Risk Mitigation : Make informed decisions on market entry, partnerships, and resource allocation in South Korea with comprehensive regional analysis and forward-looking market projections.

    Frequently asked questions

    What is the current size of South Korea's veterinary biologics market?

    South Korea's veterinary biologics market is valued at USD 16.27 million in 2025.

    What is the projected market size for South Korea's veterinary biologics by 2030?

    South Korea's veterinary biologics market is projected to reach USD 20.68 million by 2030.

    What is the growth rate of South Korea's veterinary biologics market?

    South Korea's veterinary biologics market is expected to grow at a CAGR of 4.9% from 2025 to 2030.

    What factors are driving growth in South Korea's veterinary biologics market?

    Growth in South Korea is driven by rising pet ownership, advanced veterinary infrastructure, regulatory support for innovation, and emphasis on food safety and biosecurity.

    Which segments are most significant in South Korea's veterinary biologics market?

    South Korea's market includes companion animal vaccines and therapeutics, as well as livestock biologics focused on disease prevention and food safety.

    RESEARCH METHODOLOGY

    This study extensively used both primary and secondary sources. The research process examined various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, market dynamics, and strategies of major players.

    Secondary Research

    This research involved the use of comprehensive secondary sources, including directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was employed to gather information for an extensive, technical, market-focused, and commercial analysis of the veterinary biologics market. It also helped obtain crucial details about key players, market classification, and segmentation based on industry trends at the most detailed levels, as well as significant developments related to market and technology perspectives. Additionally, a database of major industry leaders was created using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources from the supply side include project managers, sales managers, marketing managers, business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary biologics market. Primary sources from the demand side consist of professionals from veterinary hospitals and clinics, diagnostic labs, academic and research institutes, and pet owners.

    A breakdown of the primary respondents is provided below:

    Veterinary Biologics Market

    Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

    Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

    Source: MarketsandMarkets Analysis

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The total size of the veterinary biologics market was determined through data triangulation from three different approaches, as outlined below. After each approach, a weighted average was calculated based on the level of assumptions used in each method.

    Veterinary Biologics Market

    Data Triangulation

    After defining the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown methods were used where applicable to complete the overall market analysis and determine accurate statistics for all segments and subsegments. The following figure illustrates the market validation, source structure, and data triangulation approach used in the market analysis process.

    Market Definition

    The veterinary biologics market includes all USDA-regulated biologic products, such as monoclonal antibodies, immunoglobulins, immunomodulators, and diagnostic kits, which are used for the prevention, diagnosis, or treatment of animal diseases. These products serve companion animals, livestock, and poultry across veterinary clinics, hospitals, diagnostic labs, and farm or herd settings, enabling veterinarians and animal health professionals to provide targeted immune-based interventions and rapid diagnostic testing. This allows infected animals to be identified quickly for faster treatment, containment, or herd management decisions.

    Stakeholders

    • Veterinary Biologics Manufacturers
    • Animal Healthcare Product Manufacturers
    • Veterinary Biologics Distributors and Wholesalers
    • Animal Welfare Associations
    • Veterinary Clinics and Care Centers
    • Research And Consulting Firms
    • Veterinary Research and Development Organizations
    • Contract Manufacturing Organizations
    • Venture Capitalists

    Report Objectives

    • To define, describe, and forecast the veterinary biologics market by product type, animal type, route of administration, application, end user, and region.
    • To provide detailed information about the key factors, such as drivers, restraints, opportunities, challenges, and industry trends, influencing the market growth
    • To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI on veterinary biologics market, case study analysis, adjacent market analysis, unmet needs/end user expectations in veterinary biologics market, and trends/disruption impacting customer business in the market
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To strategically analyze the market in five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market

     

    Get the Full Veterinary Biologics Market Report

    Full forecast, segment splits, and company analysis for all Veterinary Biologics Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status